The NAD-dependent deacetylase SIRT1 can be oncogenic or tumor suppressive depending on the tissue. Little is known about the role of SIRT1 in non-small cell lung carcinoma (NSCLC), one of the deadliest cancers, that is frequently associated with mutated K-RAS Therefore, we investigated the effect of SIRT1 on K-RAS-driven lung carcinogenesis. We report that SIRT1 protein levels are downregulated by oncogenic K-RAS in a MEK and PI3K-dependent manner in mouse embryo fibroblasts (MEFs), and in human lung adenocarcinoma cell lines. Furthermore, Sirt1 overexpression in mice delays the appearance of K-Ras-driven lung adenocarcinomas, reducing the number and size of carcinomas at the time of death and extending survival. Consistently, lower levels of SIRT1 are associated with worse prognosis in human NSCLCs. Mechanistically, analysis of mouse Sirt1-Tg pneumocytes, isolated shortly after K-Ras activation, reveals that Sirt1 overexpression alters pathways involved in tumor development: proliferation, apoptosis, or extracellular matrix organization. Our work demonstrates a tumor suppressive role of SIRT1 in the development of K-RAS-driven lung adenocarcinomas in mice and humans, suggesting that the SIRT1-K-RAS axis could be a therapeutic target for NSCLCs.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6123659 | PMC |
| http://dx.doi.org/10.15252/embr.201643879 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A new ferrocene derivative blocks K-Ras localization and function by oxidative modification at His95.
Life Sci Alliance
November 2023
Department of Biochemistry and Molecular Biology, Boonshoft School of Medicine, Wright State University, Dayton, OH, USA
Article Synopsis
- Ras proteins are crucial for cell processes and are implicated in cancer; mutations in K-Ras, a Ras isoform, are common in human tumors.
- A novel ferrocene derivative was tested and found to increase reactive oxygen species (ROS) levels, inhibiting the growth of K-Ras-driven pancreatic and lung cancers by disrupting K-Ras's functions at the plasma membrane.
- The study highlights the importance of K-Ras's His95 residue, which may be oxidized by ROS, indicating that the redox system affects K-Ras signaling and growth in these cancers.
Toll-like receptors 2, 4, and 9 modulate promoting effect of COPD-like airway inflammation on K-ras-driven lung cancer through activation of the MyD88/NF-ĸB pathway in the airway epithelium.
Front Immunol
June 2023
Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Introduction: Toll-like receptors (TLRs) are an extensive group of proteins involved in host defense processes that express themselves upon the increased production of endogenous damage-associated molecular patterns (DAMPs) and pathogen-associated molecular patterns (PAMPs) due to the constant contact that airway epithelium may have with pathogenic foreign antigens. We have previously shown that COPD-like airway inflammation induced by exposure to an aerosolized lysate of nontypeable (NTHi) promotes tumorigenesis in a K-ras mutant mouse model of lung cancer, CCSP/LSL-K-ras (CC-LR) mouse.
Methods: In the present study, we have dissected the role of TLRs in this process by knocking out TLR2, 4, and 9 and analyzing how these deletions affect the promoting effect of COPD-like airway inflammation on K-ras-driven lung adenocarcinoma.
Ras proteins are membrane-bound GTPases that regulate essential cellular processes at the plasma membrane (PM). Constitutively active mutations of K-Ras, one of the three Ras isoforms in mammalian cells, are frequently found in human cancers. Ferrocene derivatives, which elevate cellular reactive oxygen species (ROS), have shown to block the growth of non-small cell lung cancers (NSCLCs) harboring oncogenic mutant K-Ras.
View Article and Find Full Text PDFCisplatin and gemcitabine exert opposite effects on immunotherapy with PD-1 antibody in K-ras-driven cancer.
J Adv Res
September 2022
Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China; Metabolic Innovation Center, Sun Yat-Sen University, Guangzhou 510060, China. Electronic address:
Article Synopsis
- Immunochemotherapy using PD-1/PD-L1 antibodies combined with chemotherapeutic agents is a growing cancer treatment, but optimal drug combinations are still being researched.
- This study focuses on how the chemotherapeutic drugs gemcitabine and cisplatin affect the effectiveness of PD-1 antibody treatment in cancers driven by the K-ras mutation, which often overexpresses PD-L1.
- Results indicate that gemcitabine reduces the effectiveness of PD-1 antibodies by inhibiting CD8 T cell infiltration, while cisplatin enhances the treatment’s efficacy by activating CD8 T cells, suggesting that choosing the right chemotherapy drug is crucial for successful immunochemotherapy.
The deubiquitinase USP16 functions as an oncogenic factor in K-RAS-driven lung tumorigenesis.
Oncogene
September 2021
State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
K-RAS mutation and molecular alterations of its surrogates function essentially in lung tumorigenesis and malignant progression. However, it remains elusive how tumor-promoting and deleterious events downstream of K-RAS signaling are coordinated in lung tumorigenesis. Here, we show that USP16, a deubiquitinase involved in various biological processes, functions as a promoter for the development of K-RAS-driven lung tumor.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!